NRX Pharmaceuticals, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $2.45
- 52-Week Range
- $1.62 – $5.06
- Market Cap
- $124.12M
- P/E (TTM)
- —
- EPS (TTM)
- -0.33
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -70.06%
- Gross Margin
- 39.97%
- Operating Margin
- -556.55%
- Profit Margin
- 0.00%
- Current Ratio
- 0.76
- Debt/Equity
- —
- Total Debt
- $978.00K
- Free Cash Flow
- $-14.58M
- Revenue Growth
- 378.90%
- Earnings Growth
- —
- Enterprise Value
- $105.27M
Market Snapshot
About
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for pain management and psychiatric disorders. The company focuses on NMDA receptor antagonists and other neurological targets to treat conditions including post-traumatic stress disorder and chronic pain. NRX is advancing multiple drug candidates through clinical trials and regulatory pathways.